Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Morphic Therapeutic (NASDAQ: MORF) is a clinical-stage biopharmaceutical company applying its proprietary MInT (Morphic Integrin Technology) Platform to develop a new generation of oral integrin therapies. Integrins are cell surface receptors crucial for cell adhesion and signaling; their dysregulation is implicated in various serious chronic diseases. Morphic aims to discover and develop highly selective, orally-bioavailable small molecule modulators of integrins to treat conditions such as autoimmune disorders (like ulcerative colitis and Crohn's disease), fibrosis, and NASH (non-alcoholic steatohepatitis). Their innovative approach seeks to overcome historical limitations of integrin-targeted therapies, focusing on oral administration and improved therapeutic profiles.
Serves as the primary center for the company's research and development efforts, clinical operations leadership, corporate strategy, and general administrative functions.
The headquarters comprises modern laboratory and office spaces designed to support cutting-edge scientific research and collaboration. It is situated within a life sciences campus environment.
Morphic fosters a science-driven, innovative, and collaborative work culture. Employees are typically focused on advancing novel therapeutics with a strong emphasis on teamwork, scientific rigor, and addressing unmet patient needs.
The Waltham headquarters is pivotal for driving Morphic's pipeline of oral integrin therapeutics, from initial discovery through clinical development stages, and for managing the company's strategic growth and operations.
Morphic Therapeutic is headquartered in the United States. While its primary research and corporate functions are centralized, the company's clinical trial activities for its therapeutic candidates, such as MORF-057, often involve multiple sites and patient populations internationally. Its business development and potential commercialization strategies also maintain a global outlook to reach patients worldwide.
35 Gatehouse Drive, Building A
Waltham
MA
USA
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Morphic Therapeutic' leadership includes:
Morphic Therapeutic has been backed by several prominent investors over the years, including:
Over the last 12 months, Morphic Therapeutic notably strengthened its executive leadership by appointing a new Chief Business Officer to drive corporate strategy and business development initiatives.
Discover the tools Morphic Therapeutic uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Morphic Therapeutic most commonly uses the email format combining the first initial of an employee's name with their full last name. This is a standard convention in many biotechnology and pharmaceutical companies.
flast@morphictx.com
Format
jdoe@morphictx.com
Example
85%
Success rate
Morphic Therapeutic IR • May 8, 2024
Morphic Therapeutic announced its Q1 2024 financial results, highlighting progress in its clinical programs, particularly MORF-057 for ulcerative colitis and Crohn's disease. The company also provided updates on its cash runway and upcoming milestones....more
Morphic Therapeutic IR • March 4, 2024
Morphic announced the strategic appointment of Alexey Eletsky, Ph.D., as its new Chief Business Officer. Dr. Eletsky brings significant biopharma industry experience to lead Morphic's business development and corporate strategy....more
Morphic Therapeutic IR • January 4, 2024
Morphic outlined its strategic priorities and anticipated milestones for 2024, focusing on the advancement of MORF-057 through Phase 2b studies (EMERALD-1 and EMERALD-2) and the continued development of its broader pipeline of oral integrin candidates....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Morphic Therapeutic, are just a search away.